Intervention Protocol

You have free access to this content

Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients

  1. Marie-Therese Sickinger1,
  2. Bastian von Tresckow2,
  3. Carsten Kobe3,
  4. Andreas Engert1,
  5. Nicole Skoetz1,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 4 JUN 2013

DOI: 10.1002/14651858.CD010533


How to Cite

Sickinger MT, von Tresckow B, Kobe C, Engert A, Skoetz N. Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010533. DOI: 10.1002/14651858.CD010533.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany

  3. 3

    University Hospital of Cologne, Cologne, Germany

*Nicole Skoetz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. nicole.skoetz@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 4 JUN 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of interim [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging for treatment modification in patients with Hodgkin lymphoma by critical, systematic and statistical analysis of randomised controlled trials, regarding overall survival, progression-free survival, response rate, adverse events and quality of life.